gamma-aminobutyric acid has been researched along with Chronic Kidney Diseases in 10 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin relieved itching in 47 patients (66%)." | 9.16 | Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012) |
| "Gabapentin or pregabalin relieved itching in 85% of 71 consecutively treated CKD patients." | 9.16 | Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012) |
| "To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD." | 7.81 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common." | 7.81 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "The average pretreatment pruritus score was 9." | 6.78 | Use of pregabalin in the management of chronic uremic pruritus. ( Grenader, T; Lifschitz, M; Shavit, L; Slotki, I, 2013) |
| "Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common." | 5.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| " We compared dosing and side effects in 34 CKD/ESKD patients with similar patients receiving HD (n = 15)." | 5.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Pruritus and restless legs syndrome (RLS) frequently affect patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), impacting the quality of life." | 5.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Gabapentin relieved itching in 47 patients (66%)." | 5.16 | Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012) |
| "Gabapentin or pregabalin relieved itching in 85% of 71 consecutively treated CKD patients." | 5.16 | Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012) |
| "Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak." | 4.95 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| "To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD." | 3.81 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common." | 3.81 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "The average pretreatment pruritus score was 9." | 2.78 | Use of pregabalin in the management of chronic uremic pruritus. ( Grenader, T; Lifschitz, M; Shavit, L; Slotki, I, 2013) |
| "Any intervention for the treatment of uremic pruritus was included." | 2.55 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| "Uremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients." | 2.55 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| "Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common." | 1.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| " We compared dosing and side effects in 34 CKD/ESKD patients with similar patients receiving HD (n = 15)." | 1.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Pruritus and restless legs syndrome (RLS) frequently affect patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), impacting the quality of life." | 1.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Treatment with hydralazine at hypotensive dose for 12 weeks also failed to affect the proteinuria in 5 of 6 nephrectomized CKD rats." | 1.40 | Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats. ( Ayajiki, K; Funai, A; Kobuchi, S; Matsumura, Y; Ohkita, M; Suzuki, R; Tanaka, R; Tsutsui, H; Yazawa, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalantari, S | 1 |
| Chashmniam, S | 1 |
| Nafar, M | 1 |
| Samavat, S | 1 |
| Rezaie, D | 1 |
| Dalili, N | 1 |
| Simonsen, E | 1 |
| Komenda, P | 1 |
| Lerner, B | 1 |
| Askin, N | 1 |
| Bohm, C | 1 |
| Shaw, J | 1 |
| Tangri, N | 1 |
| Rigatto, C | 1 |
| Rayner, H | 1 |
| Baharani, J | 1 |
| Smith, S | 1 |
| Suresh, V | 1 |
| Dasgupta, I | 1 |
| Kobuchi, S | 1 |
| Tanaka, R | 1 |
| Funai, A | 1 |
| Suzuki, R | 1 |
| Yazawa, M | 1 |
| Tsutsui, H | 1 |
| Ohkita, M | 1 |
| Ayajiki, K | 1 |
| Matsumura, Y | 1 |
| Mettang, T | 1 |
| Kremer, AE | 1 |
| Cheikh Hassan, HI | 1 |
| Brennan, F | 1 |
| Collett, G | 1 |
| Josland, EA | 1 |
| Brown, MA | 1 |
| Gargiulo, R | 1 |
| Suhail, F | 1 |
| Lerma, EV | 1 |
| Kitajima, S | 1 |
| Iwata, Y | 1 |
| Furuichi, K | 1 |
| Sagara, A | 1 |
| Shinozaki, Y | 1 |
| Toyama, T | 1 |
| Sakai, N | 1 |
| Shimizu, M | 1 |
| Sakurai, T | 1 |
| Kaneko, S | 1 |
| Wada, T | 1 |
| Gopaluni, S | 1 |
| Sherif, M | 1 |
| Ahmadouk, NA | 1 |
| Shavit, L | 1 |
| Grenader, T | 1 |
| Lifschitz, M | 1 |
| Slotki, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus[NCT04650750] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Prospective Randomized Study Evaluating the Efficacy of the Spherical Absorptive Carbon AST-120 in Hemodialysis Patients With Uremic Pruritus..[NCT04639674] | Phase 4 | 100 participants (Actual) | Interventional | 2020-07-02 | Completed | ||
| Identifying a Cardiorenal Protective Diet in a Lower-income African American Population With Chronic Kidney Disease at Risk for Cardiovascular Disease.[NCT04117204] | 101 participants (Actual) | Interventional | 2019-06-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for gamma-aminobutyric acid and Chronic Kidney Diseases
| Article | Year |
|---|---|
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Uremic pruritus.
Topics: Acupuncture Therapy; Amines; Anti-Inflammatory Agents; Calcium Channel Blockers; Cyclohexanecarboxyl | 2015 |
Cardiovascular disease and chronic kidney disease.
Topics: Cardiovascular Diseases; Coronary Artery Disease; gamma-Aminobutyric Acid; Heart Diseases; Humans; P | 2015 |
Interventions for chronic kidney disease-associated restless legs syndrome.
Topics: Amines; Anticonvulsants; Ascorbic Acid; Cyclohexanecarboxylic Acids; Dopamine Agonists; Exercise The | 2016 |
2 trials available for gamma-aminobutyric acid and Chronic Kidney Diseases
| Article | Year |
|---|---|
Uraemic pruritus: relief of itching by gabapentin and pregabalin.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Comorbidity; Cyclohexanecarboxylic Acids; Dose-R | 2012 |
Use of pregabalin in the management of chronic uremic pruritus.
Topics: Aged; Analgesics; Anticonvulsants; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Male; P | 2013 |
4 other studies available for gamma-aminobutyric acid and Chronic Kidney Diseases
| Article | Year |
|---|---|
A Noninvasive Urine Metabolome Panel as Potential Biomarkers for Diagnosis of T Cell-Mediated Renal Transplant Rejection.
Topics: Acute Disease; Adenosine Diphosphate; Adult; Biomarkers; Cholesterol Esters; Cross-Sectional Studies | 2020 |
Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Autonom | 2014 |
Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma- | 2015 |
Messenger RNA expression profile of sleep-related genes in peripheral blood cells in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Female; gamma-Aminobutyric Acid; Gene Expression Prof | 2016 |